BG
BMY.RT

Bellevue Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bellevue Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,617,446
Closed -$2.5M – 237
2020
Q4 		$2.5M Buy
3,617,446
+2,817,446
+352% +$6M 0.03% 141
2020
Q3 		$1.8M Hold
800,000
– – 0.02% 146
2020
Q2 		$2.86M Sell
800,000
-16,600
-2% -$59.9K 0.04% 131
2020
Q1 		$3.1M Hold
816,600
– – 0.06% 119
2019
Q4 		$2.46M Buy
+816,600
New +$2.12M 0.04% 126

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Bellevue Group's BMY.RT Position: Q1 2021 in Review

Bellevue Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 3,617,446 shares — an estimated $2.5M sold.

Bellevue Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.1M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Bellevue Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Bellevue Group sold 3,617,446 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2.5M.
  • Bellevue Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Bellevue Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.1M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.